Market Entry & Expansion Strategy

Expanding into global markets requires a structured approach that includes device classification across jurisdictions, a regulatory pathway selection (e.g., CE marking, licensing, registration), an authorized representative and importer requirements, labeling, language, and UDI compliance.

Strategic Considerations for Manufacturers

Selecting the appropriate regulatory pathway for a new market is not simply a compliance decision. It is a business decision that affects time to market, development costs, clinical and testing requirements, and competitive positioning.

Early regulatory planning can prevent costly delays, reduce risk, and accelerate commercialization.

Quality System Alignment (ISO 13485-Centric)

A globally scalable quality system is built on ISO 13485:2016 as the foundational framework that is integrated with FDA’s Quality Management System Regulation (QMSR).

This also supports EU MDR conformity assessment expectations, Health Canada MDSAP requirements, and China GMP compliance. The key is to harmonize quality systems across jurisdictions to duplication and audit burden.

Risk Management and Clinical Evidence

Global regulators increasingly emphasize risk management integration (ISO 14971), clinical evaluation and evidence generation, post-market clinical follow-up (PMCF), and real-world data utilization.

Post-Market Surveillance and Vigilance

Post-market obligations are expanding globally, in areas of complaint handling and trending, adverse event reporting (MDR, vigilance systems), CAPA integration, signal detection, and risk reassessment.

A unified PMS system will result in fewer compliance gaps across regions.

Global Supply Chain & Supplier Controls

International operations require supplier qualification and monitoring, foreign manufacturer audits, import controls and documentation, traceability, and UDI implementation.